H55 Anticholinergic drug burden and cognitive function in huntington’s disease

    loading  Checking for direct PDF access through Ovid



Individuals with Huntington’s disease may present with difficulties in cognition. Cognition affects an individual’s care needs, including the need for residential care.1 Medical comorbidities compound difficulties for those with HD and their caregivers. Psychotropic and other medications may have significant anticholinergic side effects,2 these may be cumulative in nature and affect cognition. The Drug Burden Index (DBI)3 4 is a measure of exposure to anticholinergic medications. It was reported to be independently associated with physical and cognitive function in community dwelling older persons.


Specific Aim 1: Does anticholinergic drug burden score impact cognitive function? Specific Aim 2: What is the role of psychotropic medications in generating this anticholinergic burden?


De-identified data was obtained from the Enroll-HD and Registry Specified Dataset. Medication data is maintained by the Uppsala Monitoring Centre (UMC). We will combine this data with psychometric tests available. DBI will be calculated at years 1 (baseline), 2 and 4. A measure of the area under the curve for DBI (AUCDB) over the whole study period will be calculated.


3000 Cognitive assessments were identified ranging from 1 to 4 years of follow up in the dataset. MMSE scores varied from 2 to 30. Data examination revealed significant co-morbidities, which will be correlated with Drug Burden Index scores.


The effects and burden of anticholinergic medicines in individuals with Huntington’s disease is significant. The impact of the anticholinergic burden score upon cognitive function must be carefully monitored. All medications should be regularly reviewed to maximize cognitive function.

Related Topics

    loading  Loading Related Articles